Wilmot scientists are supported by grants from a variety of sources, including the National Cancer Institute, several nationally respected cancer foundations, and industry groups. However, community and regional support for our research is also critical. We rely on donations to boost existing projects, to recruit top-flight scientists, and to seed newly developing hypotheses with the data necessary to compete for larger grants. Thank you for considering a research gift to Wilmot. Our scientific programs (listed below) set us apart from all other cancer providers in upstate New York.
Make a secure online gift today »
Our researchers are studying how to disrupt entire gene networks that control the activity of many cancers, instead of focusing on single gene mutations. The goal is to develop the next generation of targeted therapies so that personalized treatment can reach more people. This team also investigates ways to repurpose existing FDA-approved drugs as cancer therapy.
This team studies the way in which cancers arise from the precursors to red and white blood cells and platelets. Their focus is on the primitive cancer stem cells that drive leukemia, the vessels and tissue in bone marrow (known as the microenvironment), and clinical trials to test promising new lymphoma and leukemia drugs.
For the physicians and scientists on this team, collaboration is critical. Together they are finding ways to apply concepts of biology and genomics to the urgent needs of patients. Our primary focus is on genitourinary cancers (including prostate, bladder, kidney and testicular), gastrointestinal cancers (pancreas, liver, colon, esophageal), breast cancer and brain cancer.
With a long history of finding ways to help patients cope with side effects of treatment, this team is continuing in that strong tradition while also expanding into survivorship science. Whether it’s preventing radiation harm or understanding how yoga therapy helps insomnia, the goal is to improve the experience during every step of the journey at Wilmot.